14 years of historical data (2012–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ardelyx, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $1.4B | $1.2B | $1.4B | $452M | $115M | $145M | $121M | $25M | $78M | $142M |
| Enterprise Value | $1.7B | $1.5B | $1.3B | $1.4B | $393M | $88M | $110M | $-2608236 | $-4400586 | $3M | $68M |
| P/E Ratio → | -25.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.91 | 3.45 | 3.57 | 10.93 | 8.67 | 11.35 | 19.17 | 22.95 | 9.65 | 1.86 | 5.93 |
| P/B Ratio | 9.46 | 8.42 | 6.88 | 8.15 | 4.60 | 1.39 | 1.15 | 0.65 | 0.22 | 0.56 | 0.74 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.79 | 3.84 | 11.20 | 7.53 | 8.69 | 14.47 | -0.49 | -1.69 | 0.07 | 2.82 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Ardelyx, Inc. earns an operating margin of -10.1%. Operating margins have expanded from -50.8% to -10.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -36.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.3% | 90.3% | 84.8% | 85.7% | 92.1% | 90.1% | 98.1% | 88.6% | 82.1% | 80.0% | 94.6% |
| Operating Margin | -10.1% | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% | -1199.0% | -1728.1% | -3488.6% | -155.0% | -469.9% |
| Net Profit Margin | -15.1% | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | -1245.7% | -1797.8% | -3502.0% | -153.2% | -467.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.2% | -36.2% | -23.0% | -49.8% | -74.3% | -151.6% | -60.3% | -62.8% | -71.6% | -38.7% | -74.4% |
| ROA | -13.1% | -13.1% | -10.7% | -27.1% | -39.5% | -90.0% | -40.9% | -42.9% | -53.5% | -34.7% | -68.1% |
| ROIC | -10.8% | -10.8% | -9.1% | -39.6% | -101.4% | -158.3% | -88.8% | -91.8% | -90.8% | -53.5% | -140.6% |
| ROCE | -10.6% | -10.6% | -9.2% | -34.1% | -57.6% | -114.2% | -44.2% | -45.3% | -59.5% | -39.0% | -74.5% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $140M ($208M total debt minus $68M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.25 | 0.89 | 0.34 | 0.37 | 0.55 | 0.44 | 0.31 | 0.42 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.84 | 0.51 | 0.21 | -0.61 | -0.33 | -0.28 | -0.66 | -0.26 | -0.54 | -0.39 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -1.39 | -7.13 | -12.57 | -34.28 | -17.80 | -15.94 | -25.73 | — | — |
Short-term solvency ratios and asset-utilisation metrics
Ardelyx, Inc.'s current ratio of 4.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.88x to 4.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.31 | 4.31 | 4.58 | 4.88 | 2.34 | 2.53 | 6.87 | 11.36 | 10.02 | 8.39 | 10.62 |
| Quick Ratio | 4.11 | 4.11 | 4.31 | 4.64 | 2.29 | 2.53 | 6.87 | 11.36 | 10.02 | 8.39 | 10.62 |
| Cash Ratio | 2.99 | 2.99 | 3.21 | 3.66 | 1.89 | 2.21 | 6.56 | 11.14 | 9.48 | 7.50 | 10.46 |
| Asset Turnover | — | 0.81 | 0.77 | 0.42 | 0.27 | 0.07 | 0.04 | 0.02 | 0.01 | 0.27 | 0.11 |
| Inventory Turnover | 2.23 | 2.23 | 2.39 | 1.43 | 1.25 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 64.38 | 63.13 | 64.61 | 54.12 | 18.15 | — | 51.84 | 711.94 | 93.82 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ardelyx, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $241M | $235M | $219M | $159M | $104M | $90M | $64M | $56M | $47M | $40M |
Compare ARDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ARDXYou | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| TBPH | $925M | -15.9 | — | — | 100.0% | -72.9% | -29.0% | -17.2% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARDX stacks up against sector leader United Therapeutics Corporation.
Start ComparisonArdelyx, Inc.'s current P/E ratio is -25.2x. This places it at the 50th percentile of its historical range.
Ardelyx, Inc.'s return on equity (ROE) is -36.2%. The historical average is -57.5%.
Based on historical data, Ardelyx, Inc. is trading at a P/E of -25.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ardelyx, Inc. has 90.3% gross margin and -10.1% operating margin.